ALVET.PA
TheraVet SA [ALVET.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALVET.PA Stock Summary
In the News
ALVET.PA Financial details
Company Rating
-
Market Cap
2.68M
Income
-3.06M
Revenue
756.12K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-1.9
Forward P/E
-
PEG
-0.15
P/S
2.81
P/B
0.6
P/C
-
P/FCF
-2.91
Quick Ratio
2.94
Current Ratio
3.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.95
EPS next Y
-
EPS next Q
-
EPS this Y
73.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-81.88%
EPS Q/Q
100%
-
-
-
-
SMA20
-20%
SMA50
-27.27%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-25%
ROE
-28%
ROC
-0.33%
Gross Margin
-62%
Oper. Margin
-173%
Profit Margin
-148%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.81-3.08
52W High
-
52W Low
-
RSI
28.87
Rel Volume
-
Avg Volume
9.86K
Volume
Perf Week
0%
Perf Month
-25.45%
Perf Quarter
-
Perf Half Y
-31.95%
-
-
-
-
Beta
-0.258
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.082
Change
0%
Company Profile
- Volume Average 9.86K
- Market Capitalization 2.68M
- Employee 7
- CEO Mr. Enrico Bastianelli M.B.A., M.D., MBA
- Headquarters Charleroi,BE
- IPO Date 2021-06-17
-
Website
https://www.thera.vet/en 
TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET for osseointegration and bone remodelling; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid with anti-inflammatory properties that promotes the effect of active components, as well as acts as a cell colonization supporting tissue regeneration. The company was incorporated in 2017 and is headquartered in Jumet, Belgium.
